RVV — Revive Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$10.46m
- CA$10.41m
- 11
- 29
- 70
- 28
Annual cashflow statement for Revive Therapeutics, fiscal year end - June 30th, CAD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -5.38 | -20.1 | -17.8 | -6.32 | -5.62 |
| Depreciation | |||||
| Non-Cash Items | 3.34 | 11.1 | 1.2 | 1.04 | 2.51 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.503 | 0.706 | 3.54 | -0.748 | -0.186 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -2.52 | -8.31 | -13.1 | -6.03 | -3.29 |
| Capital Expenditures | 0 | -3 | 0 | — | — |
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.142 | 0.281 | 0 | — | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0.142 | -2.72 | 0 | — | — |
| Financing Cash Flow Items | -0.295 | -2.45 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.28 | 26.2 | 0.376 | 4.2 | 1.98 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.906 | 15.2 | -12.7 | -1.83 | -1.31 |